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Abstract
Background Liver stiffness measurement (LSM) can
assess liver fibrosis in patients with chronic hepatitis B
(CHB). We evaluated whether LSM can be used to assess
changes in liver fibrosis during antiviral treatment using
nucleos(t)ide analogs in patients with CHB.
Methods We recruited 41 patients with CHB who had
significant liver fibrosis, normal or slightly elevated serum
alanine aminotransferase (ALT) levels (B2 9 upper limit
of normal), and detectable serum hepatitis B virus DNA
before antiviral treatment. Patients in Group 1 (n = 23)
and Group 2 (n = 18) underwent follow-up LSM after
antiviral treatment for 1 and 2 years, respectively.
Results The mean age, ALT and LSM value of all patients
(34 men and 7 women) before antiviral treatment were
46.6 ± 9.5 years, 40.6 ± 17.2 IU/L and 12.9 ± 8.6 kPa,
respectively. Hepatitis B e antigen (HBeAg) was detected in
31 patients (75.6%). Fibrosis stage was F2 in 12 (29.3%), F3
in 6 (14.6%) and F4 in 23 (56.1%) patients. After antiviral
treatment, LSM values and DNA positivity decreased sig-
nificantly as compared to baseline (P = 0.018 and
P \ 0.001 in Group 1; P = 0.017 and P \ 0.001 in Group 2,
respectively), whereas ALT levels were unchanged
(P = 0.063 in Group 1; P = 0.082 in Group 2).
Conclusions Our preliminary data suggest that LSM can
be used to assess liver fibrosis regression after antiviral
treatment using nucleos(t)ide analogs in patients with CHB.
Keywords Alanine aminotransferase 
Chronic hepatitis B  Liver fibrosis  Liver stiffness
measurement  Nucleos(t)ide analog  Transient
elastography
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LB Liver biopsy
HBV Hepatitis B virus
HCV Hepatitis C virus
CHB Chronic hepatitis B
CHC Chronic hepatitis C
CLD Chronic liver disease
LSM Liver stiffness measurement
ALT Alanine aminotransferase
AST Aspartate aminotransferase
ULN Upper limit of normal
HBsAg Hepatitis B surface antigen
HBeAg Hepatitis B e antigen
kPa Kilopascals
IQR Interquartile range
API Age–platelet count index
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Introduction
Chronic hepatitis B (CHB) is a chronic inflammatory
condition that results in the formation of fibrous tissue and
may lead to architectural distortion and persistent damage
of the liver. Until recently, liver fibrosis and cirrhosis were
generally considered to be irreversible [1, 2]. However,
several studies using serial liver biopsies (LBs) have
reported that several therapeutic interventions can produce
histological improvement, including liver fibrosis regres-
sion [3–7]. Among these therapeutic interventions, nucle-
os(t)ide analogs that suppress hepatitis B virus (HBV)
replication eliminated HBV DNA in 30–70% of cases and
were significantly associated with liver fibrosis regression
by reducing liver inflammation and cellular damage [8–11].
Because the prognosis and management of patients with
CHB, as well as other chronic liver diseases (CLDs),
depend strongly on the degree of liver fibrosis, the
assessment of liver fibrosis regression is helpful to clini-
cians [12]. However, follow-up LB for confirming liver
fibrosis regression during or after antiviral treatment is
troublesome except consenting subjects. Therefore, a non-
invasive method to assess liver fibrosis regression in
patients with CHB who have undergone antiviral treatment
would be highly useful.
Liver stiffness measurement (LSM) using FibroScan
allows the accurate assessment of liver fibrosis in patients
with CHB and chronic hepatitis C (CHC) [13–15].
Although there have been several longitudinal investiga-
tions of patients with CHC [16–18], no longitudinal follow-
up study has examined patients with CHB receiving
antiviral treatment. Therefore, aims of our study were to
evaluate whether LSM, rather than LB, can be used to
assess changes in liver fibrosis during antiviral treatment
using nucleos(t)ide analogs in patients with CHB and to
compare the performance of LSM and other non-invasive
methods in assessing liver fibrosis regression.
Patients and methods
Patients
In this retrospective cohort study, all data were collected
from the database of Severance Hospital, Yonsei University
College of Medicine, Seoul, Korea. Between January and
August 2007, we recruited 41 patients with CHB who
showed significant liver fibrosis (Cstage F2 according to
the METAVIR scoring system) on LB, normal or slightly
elevated serum alanine aminotransferase (ALT) levels
[\2 9 upper limit of normal (ULN)], detectable serum
HBV DNA by hybridization capture assay before anti-
viral treatment [19], and no ALT fluctuation (C2 9 ULN)
during antiviral treatment. The study protocol conformed to
the ethical guidelines of the 1975 Helsinki declaration and
was approved by our independent institutional review
board.
Patients with other CLDs, such as liver cancer, co-
infection with hepatitis C virus (HCV), or human immu-
nodeficiency virus and those with co-morbidities associated
with HBV, such as non-alcoholic steatohepatitis, primary
sclerosing cholangitis, or primary biliary cirrhosis, were
excluded. Patients with a history of alcohol ingestion over
40 g/day for more than 5 years, previous liver resection
surgery, liver transplantation, or evidence of cardiac or renal
failure (defined as a serum creatinine levels C1.5 mg/dL)
were also excluded. Patients with an unreliable LSM
[\10 successful acquisitions, a success rate \60%, an
interquartile range (IQR) over median ratio lower than
30%, or measurement on a different day from LB; n = 4]
or an unsuitable LB for fibrosis staging (\15 mm or 6
portal tracts; n = 2) were also excluded.
From the medical records, we collected data on age,
gender, body mass index, liver histology and LSM values.
The following laboratory parameters were also examined
in all patients at the time of LB and LSM: ALT, total
bilirubin, serum albumin, platelet count and prothrombin
time (international normalized ratio). Hepatitis B surface
antigen (HBsAg), HBeAg and antibodies were measured
using standard enzyme-linked immunosorbent assays
(Abbott Diagnostics, Abbott Park, IL, USA). HBV DNA
levels were measured using a hybridization capture assay
(Digene Diagnostics, Gaithersburg, MD, USA).
Patients in Group 1 (n = 23) and Group 2 (n = 18)
underwent follow-up LSM and LB (optional) after antiviral
treatment for 1 and 2 years, respectively. The mean inter-
val from the starting day of antiviral treatment to follow-up
LSM and LB was 12.2 ± 1.2 months in Group 1 and
24.4 ± 0.8 months in Group 2. Nucleos(t)ide analogs used
for antiviral treatment included lamivudine (n = 16; 11
patients in Group 1 and 5 in Group 2), adefovir (n = 10; 5
in each group) and entecavir (n = 15; 7 in Group 1 and 8 in
Group 2). The selection of a nucleos(t)ide analog was made
after considering the availability of national insurance
coverage for the antiviral agent, patient demand, or the
decision of the attending clinician. The mean duration from
the day of baseline LSM to the start of antiviral treatment
was 5.7 ± 2.4 days.
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Liver stiffness measurement
Liver stiffness measurement using FibroScan was per-
formed according to previously described methods [20,
21]. Briefly, an ultrasound transducer probe is mounted on
the axis of a vibrator. Vibrations of mild amplitude (1 mm)
and low frequency (50 Hz) are transmitted by the trans-
ducer, inducing an elastic shear wave that propagates
through underlying tissues. Pulse-echo ultrasound acquisi-
tions are used to follow the propagation of the shear wave
and to measure its velocity, which is directly related to
tissue stiffness (the elastic modulus): the stiffer the tissue,
the faster the shear wave propagates. LSM measures liver
stiffness in a volume that approximates a cylinder of 1-cm
wide and 4-cm long, 25–65 mm below the skin surface.
This volume is at least 100 times larger than that of a
biopsy sample and is, therefore, far more representative of
the hepatic parenchyma.
Ten valid measurements were performed on each patient.
The success rate was calculated as the number of valid
measurements divided by the total number of measurements.
The results were expressed in kilopascals (kPa). IQR was
defined as an index of intrinsic variability of LSM corre-
sponding to the interval around LSM result containing 50%
of the valid measurements between the 25th and 75th per-
centiles. The median value was considered representative of
the elastic modulus of the liver. Only procedures with ten
valid measurements, a success rate of at least 60% and an IQR
over median ratio lower than 30% were considered reliable.
Other non-invasive methods of assessing liver fibrosis
The age–platelet index (API), aspartate aminotransferase
(AST) to platelet ratio index (APRI) and age–spleen–
platelet ratio index (ASPRI) were also evaluated for com-
parison with LSM results. The API, ARPI and ASPRI were
calculated according to Poynard, Wai and Kim et al.,
respectively (Table 1) [22–24]. ALT level was measured
using an automated chemistry analyzer (Hitachii 7600,
Tokyo, Japan). According to the manufacturer’s instruc-
tions, the ULN for ALT was determined to be 40 IU/L.
Evaluation of liver histology
The indications for LB included an assessment of the
severity of liver fibrosis and inflammation before antiviral
treatment. LB was performed twice using 16-gauze gun
biopsy sheathed cutting needle (spring loaded) (TSK
Laboratory, Tokyo, Japan) on the right lobe of the liver
under local anesthesia and ultrasound guidance. LB spec-
imens were fixed in formalin and embedded in paraffin.
4-lm-thick sections were stained with hematoxylin and
eosin and Masson’s trichrome. All liver tissue samples
were evaluated by an experienced hepatopathologist (YN
Park) who was blinded to the patients’ clinical histories.
Liver histology was evaluated according to the
METAVIR scoring system [25]. Fibrosis was staged on the
following scale of 0–4: F0, no fibrosis; F1, portal fibrosis
without septa; F2, portal fibrosis and a few septa; F3,
numerous septa without cirrhosis; and F4, cirrhosis. The
mean length of the liver samples before antiviral treatment
was 18.5 ± 1.6 mm.
Statistical analysis
Patient characteristics are presented as mean ± standard
deviation. The independent t test and Fisher’s exact test
were used to compare the baseline characteristics of
Groups 1 and 2. The paired sample t test and McNemar test
were used to compare the values pre- and post-antiviral
treatment in each patient and to identify variables that
showed a significant change during antiviral treatment.
Two-way analysis of variance test was performed to
identify the effects of each antiviral agent on the changes in
LSM value during the antiviral treatment. A two-sided
P \ 0.05 was considered to be statistically significant. All
statistical analyses were performed with SPSS 12.0 (SPSS,
Chicago, IL, USA).
Table 1 Calculation method of
noninvasive model
API age–platelet index [22],
APRI aspartate
aminotransferase to platelet
ratio index [23], AST aspartate
aminotransferase, ASPRI age–
spleen–platelet ratio index [24]
Models Calculation method
API Age (years): \30 = 0, 30–39 = 1, 40–49 = 2, 50–59 = 3, 60–69 = 4, C70 = 5
Platelet count (109 L-1): C225 = 0, 200–224 = 1, 175–199 = 2,
150–174 = 3;125–149 = 4, \125 = 5
API is the sum of the above (possible value 0–10)
APRI [(AST/ULN)/platelet count (109 L-1)] 9 100
SPRI Spleen size (cm)/platelet count (109 L-1) 9 100
ASPRI Age (years): \30 = 0, 30–39 = 1, 40–49 = 2, 50–59 = 3, 60–69 = 4, C70 = 5
ASPRI is the sum of age and SPRI
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Results
Baseline characteristics
The baseline clinical and histological characteristics of all
patients at the time of LSM and LB are shown in Table 2.
The mean age, ALT level and LSM value of all patients
(34 men and 7 women) before antiviral treatment were
46.6 ± 9.5 years, 40.6 ± 17.2 IU/L and 12.9 ± 8.6 kPa,
respectively. HBV DNA was detectable in all patients using
a hybridization capture assay, and HBeAg was detected in
31 patients (75.6%) before antiviral treatment. The fibrosis
stage was F2 in 12 (29.3%), F3 in 6 (14.6%) and F4 in 23
(56.1%) patients. There were no significantly different
variables between Groups 1 and 2. Among variables, only
fibrosis stage was significantly correlated to LSM values
before antiviral treatment (Spearman correlation coeffi-
cient, r = 0.576 and P = 0.041, data not shown).
Comparison between the values
at pre- and post-antiviral treatment
Pre- and post-antiviral treatment laboratory findings, LSM
values and several non-invasive models for assessing liver
fibrosis are summarized in Table 3. LSM values and HBV
DNA positivity decreased significantly after antiviral
treatment compared to baseline (P = 0.018 and P \ 0.001
in Group 1; P = 0.017 and P \ 0.001 in Group 2, respec-
tively), whereas ALT levels were unchanged (P = 0.063 in
Group 1, P = 0.082 in Group 2, respectively). The API,
APRI and ASPRI also failed to show a significant difference
between pre- and post-antiviral treatment values. Variations
in LSM value and ALT level are shown in Figs. 1 (Group 1)
and 2 (Group 2).
Details of Group 2 patients who underwent
follow-up LB
Follow-up LB was performed in four patients (nos. 8, 10, 12
and 13) in Group 2 (Table 4). ALT levels and LSM values
tended to decrease, all patients were HBV DNA negative
and one patient (no. 12) showed HBeAg seroconversion
Table 2 Baseline
characteristics at the time of
LSM and LB
Variables Total Group 1 Group 2 P value
(n = 41) (n = 23) (n = 18)
Male gender 34 (82.9) 19 (82.6) 15 (83.3) NS
Age (years) 46.6 ± 9.5 45.9 ± 11.4 47.6 ± 6.5 NS
Body mass index (kg/m2) 23.7 ± 2.5 23.7 ± 2.3 23.6 ± 2.8 NS
Platelet count (109 L-1) 171 ± 52 170 ± 55 172 ± 51 NS
Albumin (g/dL) 4.3 ± 0.3 4.4 ± 0.2 4.2 ± 0.3 0.072
Total bilirubin (mg/dL) 0.8 ± 0.3 0.9 ± 0.4 0.8 ± 0.4 NS
ALT (IU/L) 40.6 ± 17.2 39.7 ± 15.0 41.9 ± 20.2 NS
HBeAg positivity 31 (75.6) 15 (65.2) 16 (88.9) NS
HBV DNA positivity 41 (100.0) 23 (100.0) 18 (100.0) NS
Prothrombin time (INR) 1.02 ± 0.09 1.03 ± 0.08 1.00 ± 0.10 NS
Fibrosis at initial biopsy
F2 12 (29.3) 5 (21.7) 7 (38.9) NS
F3 6 (14.6) 3 (13.1) 3 (16.7)
F4 23 (56.1) 15 (65.2) 8 (44.4)
LSM value (kPa) 12.9 ± 8.6 13.7 ± 8.0 12.1 ± 9.6 NS
Interquartile range (kPa) 1.6 ± 1.5 2.1 ± 1.7 1.9 ± 1.1 NS
Success rate (%) 97.4 ± 6.7 97.0 ± 8.4 98 ± 3.9 NS
Table 3 Comparison between pre- and post-antiviral treatment
Group 1 (n = 23)
Pre Post P value
Body mass index (kg/m2) 23.7 ± 2.3 23.5 ± 2.2 NS
ALT (IU/L) 39.6 ± 15.0 35.9 ± 14.0 0.063
Total bilirubin (mg/dL) 0.8 ± 0.3 0.85 ± 0.3 NS
Prothrombin time (INR) 1.03 ± 0.09 1.03 ± 0.06 NS
Platelet count (109 L-1) 171 ± 20 173 ± 24 NS
LSM value (kPa) 13.7 ± 7.9 11.3 ± 5.3 0.018
11.7 (4.1–36.3) 11.8 (3.8–20.9)
HBV DNA positivity 23 (100) 1 (0.5) \0.001
HBeAg positivity 15 (65.2) 15 (65.2) NS
API 4.69 ± 2.26 4.55 ± 1.89 NS
APRI 0.85 ± 0.73 0.83 ± 0.80 NS
ASPRI 8.82 ± 3.74 8.80 ± 2.96 NS
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after antiviral treatment. Three patients (nos. 8, 10 and 13)
showed liver fibrosis regression from F3 to F2 or from F2 to
F1, whereas one patient (no. 12) showed no change in
fibrosis stage. However, patient no. 12 showed slightly
decreased portal fibrosis within the same fibrosis stage (F2)
as compared to baseline LB. Figure 3 shows histological
changes of patient no. 8 after 2 years of antiviral treatment.
Discussion
Because the degree of liver fibrosis determines prognosis
and treatment strategy for patients with CHB and CHC
[12], liver fibrosis regression during antiviral treatment can
provide additional information.
Liver biopsy has been the ‘gold standard’ for assessing
liver fibrosis, and is frequently performed as a baseline
evaluation of liver fibrosis before antiviral treatment [26].
However, LB is rarely performed to confirm liver fibrosis
regression during antiviral treatment, except in a few
studies that investigated liver fibrosis regression during
antiviral treatment using serial LBs [27, 28]. Therefore, a
non-invasive method to assess liver fibrosis regression
during antiviral treatment would enable clinicians to re-
evaluate prognoses and treatment strategies or to conduct
comparative studies on the efficacy of antiviral agents.
Currently, several simple non-invasive serologic models
for predicting liver fibrosis are available [22–24]. However,
the ability of these models to predict liver fibrosis regres-
sion during antiviral treatment has not been investigated.
According to our results, the available simple non-invasive
serologic markers do not appear to be useful in detecting
liver fibrosis regression during antiviral treatment when
compared with LSM. This result can be explained in part
by the confounding effects of extra-hepatic conditions and
the superior performance to predict liver fibrosis of LSM
has been confirmed in previous studies [20, 29]. Because
other markers, such as hyaluronic acid and type IV colla-
gen were not available in this retrospective study, further
studies with theses markers will be needed.
Recently, LSM has been accepted as a non-invasive tool
for assessing liver fibrosis. However, most investigations of
Fig. 1 Variation in LSM values
and ALT levels between pre-
and post-antiviral treatment in
patients with CHB who
underwent follow-up LSM after
1 year of antiviral treatment
using nucleos(t)ide analogs
(Group 1). LSM liver stiffness
measurement, ALT alanine
aminotransferase, LB liver
biopsy
Fig. 2 Variation in LSM values
and ALT levels between pre-
and post-antiviral treatment in
patients with CHB who
underwent follow-up LSM after
2 year of antiviral treatment
using nucleos(t)ide analogs
(Group 2). LSM liver stiffness
measurement, ALT alanine
aminotransferase, LB liver
biopsy
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LSM conducted a one-time analysis using demographic
and laboratory data obtained at the time of LB. Therefore,
there is a chance that the dynamic changes in the bio-
chemical tests before and after LB, especially ALT level,
were not incorporated in the analysis. Several recent
studies addressed this limitation by acquiring serial LSM
values and concluded that ALT level has a significant
impact on LSM [30–33]. Therefore, it has become more
evident that LSM can be influenced by high ALT levels.
Accordingly, a more recent study conducted in Hong Kong
suggested that ALT level should be incorporated into the
algorithms for diagnostic and treatment strategies in
patients with CHB [34]. Therefore, failure to consider ALT
levels may lead to less reliable or confusing results.
Among those who showed detectable HBV DNA in the
hybridization capture assay and persistently normal or
slightly elevated serum ALT levels (\2 9 ULN), a large
proportion had significant histology on LB examination,
which is an indication for antiviral treatment in South
Korea [29, 35]. Recruiting these patients enabled us to
exclude the confounding effects of high ALT levels and
specifically examine the performance of LSM in assessing
liver fibrosis regression during antiviral treatment [30–33].
Several teams have investigated dynamic changes in
LSM values during antiviral treatment in patients with
CHC who had achieved SVR. However, there is no
published longitudinal study for patients with CHB. De
Ledinghen et al. [16] evaluated liver fibrosis regression
using LSM and FibroTest in a very long-term follow-up
of HCV responders and concluded that LSM and Fibro-
Test are useful tools for the non-invasive evaluation of
liver fibrosis and monitoring the histological response
after antiviral treatment in HCV patients. Hezoda et al.
[17] reported that LSM value was significantly, but
modestly, reduced at the end of follow-up in patients with
CHC who achieved SVR in response to peginterferon and
alpha-ribavirin combination treatment. Colletao et al. [18]
also investigated liver fibrosis among long-term respond-
ers (patients with CHC and CHB) to antiviral treatment,
and concluded that LSM may reliably substitute for LB to
confirm liver fibrosis regression. More recent study
investigated the changes of LSM values during HCV
treatment and concluded that irrespective of the virolog-
ical response, treatment for HCV infection is associated
with an improvement of LSM values [36].
In this study, we controlled the confounding effects of
high ALT levels by recruiting patients with CHB showing
persistently normal or minimally elevated ALT levels
before antiviral treatment and persistent viral suppression
after antiviral treatment. The reduction in ALT levels after
antiviral treatment failed to show statistical significance
(P = 0.063 in Group 1 and P = 0.082 in Group 2), whereas
the reduction in LSM values predicted liver fibrosis
regression significantly. These results were consistent when
our study population was analyzed altogether considering
small sample size (ALT, P = 0.068 and LSM, P = 0.010,
data not shown). Furthermore, three patients (nos. 8, 10
and 13) in the 2 years of antiviral treatment group (Group 2)
Table 4 Laboratory and histologic findings of four patients in Group
2 who underwent follow-up liver biopsy
Patient #8 Patient #10 Patient #12 Patient #13
Pre Post Pre Post Pre Post Pre Post
Antiviral agent Entecavir Entecavir Entecavir Lamivudine
ALT (IU/L) 32 17 57 65 26 25 60 56
HBV DNA
(pg/mL)
3.2 \0.5 13.3 \0.5 3.4 \0.5 23.3 \0.5
HBeAg Pos Pos Pos Pos Pos Neg Pos Pos
Platelet count
(109 L-1)
187 190 236 220 221 200 231 220
Serum albumin
(g/dL)
4.0 4.5 4.6 5.0 4.3 4.1 4.3 4.2
Prothrombin
time (INR)
1.18 0.97 0.85 0.98 0.99 0.89 0.80 0.92
API 4 5 3 4 4 4 2 4
APRI 0.41 0.40 0.31 0.35 0.29 0.30 0.41 0.48
ASPRI 8.42 9.40 6.39 6.30 6.85 6.80 5.68 6.48
LSM value (kPa) 7.9 4.8 6.7 4.5 6.0 4.9 7.8 6.2
Fibrosis grade F3 F2 F2 F1 F2 F2 F2 F1
Fig. 3 Regression of liver
fibrosis from stage F3–F2 in
patient no. 8. Left septal
collagenous fibrosis of moderate
thickness is present before
antiviral treatment. Right almost
all of the portal tracts reveal
periportal fibrosis with
occasional long slender fibrosis
only (incipient septa) after
2 years of antiviral treatment
(elastic trichrome, original
magnification 940)
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underwent optional LB; data from these procedures were
used to confirm the performance of LSM in predicting liver
fibrosis regression. A previous study reported that cirrhotic
nodules appear to enlarge by expansion against septa as
well as by lysis of septa and nodules surrounded by thin
septa coalesce first, giving rise to macronodules or large
regenerative nodules [3]. Accordingly, decreased LSM
value after antiviral treatment in our current study implied
fibrosis regression by virtue of lowered volume of total
fibrosis in liver after long-term antiviral treatment.
Extrapolating our results, we might be able to consider
LSM value at the time at which ALT level falls below
2 9 ULN after antiviral treatment as a baseline and use
this value to predict subsequent liver fibrosis regression in
patients with high ALT levels (C2 9 ULN) before anti-
viral treatment. We previously showed that LSM values
required additional time to normalize even after ALT levels
had normalized in patients with acute hepatitis [37].
Therefore, if the interval between the decline in ALT level
(to\2 9 ULN) and the stabilization of LSM value can be
validated in future investigations [38], LSM could also be
used to predict liver fibrosis regression in patients with
high ALT levels (C2 9 ULN) before antiviral treatment.
An additional analysis to investigate the changes in ALT
levels and LSM values according to each antiviral agent
showed that ALT level did not change significantly in
responses to any of the examined antiviral agents
(P = 0.186 for lamivudine, P = 0.129 for adefovir and
P = 0.260 for entecavir), whereas LSM decreased signif-
icantly in patients receiving adefovir and entecavir, but not
lamivudine (P = 0.026, P = 0.014 and P = 0.101,
respectively; data not shown). In addition, no significant
difference was observed regarding the effects of each
antiviral agent and HBeAg status on LSM value after
antiviral treatment (all not significant; data not shown).
We are aware of several limitations in our study. First,
sample size was small and there is no control group (i.e. no
antiviral treatment), which is required to compare the
change in LSM values from baseline to follow-up. Second,
follow-up LB data are necessary for an exact comparison
with follow-up LSM and original LB. However, follow-up
LB was optional in this retrospective study and data were
finally obtained for only four patients from Group 2. Third,
we only recruited patients showing normal or slightly
elevated ALT before antiviral treatment and no ALT
fluctuation during antiviral treatment. Therefore, the clin-
ical usefulness of LSM should be validated by further
investigations which enroll patients with high ALT before
antiviral treatment and those with fluctuating ALT during
antiviral treatment and perform paired LB after long-term
antiviral treatment.
In conclusion, our preliminary data showed that antiviral
treatment in patients with CHB was associated with a
decrease in LSM values and suggest that LSM might be
used to assess liver fibrosis regression after antiviral
treatment using nucleos(t)ide analogs in patients with CHB
who demonstrate ALT levels \2 9 ULN before antiviral
treatment and persistent viral suppression during the course
of antiviral treatment. However, large-scaled randomized
prospective study with full paired LB and long-term fol-
low-up will be needed in the near future to validate our
conclusions.
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